Methods for treating pervasive development disorders
OwnerJoan M. Falloninventor
Life of this patent
Estimating the term…
Abstract
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.
Claims14
A method for treating a disorder with digestive enzymes, the disorder comprising Autism, ADD (attention deficit disorder) or ADHD (attention deficit hyperactivity disorder), the method comprising the steps of:
- comparing a fecal chymotrypsin level of the individual with a normal fecal chymotrypsin level;
- and
- administering digestive enzymes to the individual if the fecal chymotrypsin level of the individual is less than the normal fecal chymotrypsin level.
A method for treating an individual having an Autistic disorder using digestive enzymes, the method comprising the steps of:
- measuring a level of chymotrypsin in a stool sample of the individual;
- and
- administering digestive enzymes to the individual to promote protein digestion to improve a symptom of the disorder, if the level of chymotrypsin in the stool sample indicates that the person suffers from a deficiency in protein digestion.
Dependencies are inferred from the claim text.